DURHAM, N.C., March 30, 2017 /PRNewswire/ -- Spyryx Biosciences, a clinical-stage biopharmaceutical company developing innovative therapeutics to address severe lung diseases, announced today that John Taylor, President and CEO, will present at the Needham Healthcare Conference on Tuesday, April 4, 2017, at 2:20 p.m. ET at the Westin Grand Central Hotel in New York, N.Y.
Mr. Taylor will provide an update on the Company's corporate progress, clinical activities, and anticipated milestones for SPX-101, its lead candidate in development for the treatment of cystic fibrosis (CF), including successful Phase 1 results and plans for the upcoming clinical trials in CF patients.
SPX-101 is an inhaled peptide with a novel mechanism for regulating epithelial sodium channels in the airway. The drug is designed to increase airway hydration and promote mucociliary clearance, which is dysfunctional in CF. The mechanism of action of SPX-101 is independent of the genetic mutations that cause CF, which makes it a potential therapy for all CF patients.
|
Event: |
Needham Healthcare Conference |
|
New York, NY | |
|
Presenter: |
John Taylor, President and CEO, Spyryx |
|
Date: |
April 4, 2017 |
|
Time: |
2:20 PM Eastern Standard Time |
About Spyryx Biosciences
Spyryx Biosciences is a privately held, clinical-stage biopharmaceutical company developing innovative therapeutics to address severe lung diseases. Spyryx's lead clinical candidate, SPX-101, is a novel treatment for cystic fibrosis that has successfully completed a Phase 1 study in healthy volunteers and is advancing into Phase 2 in CF patients. The product has demonstrated a robust ability to restore mucociliary clearance in animal models of the disease and has the potential to improve lung function in cystic fibrosis patients independent of their CFTR mutation. The Spyryx leadership team and scientific staff have extensive experience in the development of respiratory medicines and work closely with a broad group of clinical and scientific experts in the pulmonary field. Spyryx is funded by a first tier syndicate of life science investors, including Canaan Partners, 5AM Ventures and Hatteras Venture Partners. Further information regarding Spyryx Biosciences is available at www.spyryxbio.com.
SOURCE Spyryx Biosciences